(ARIA) Score of Allergic Rhinitis Using Mobile Technology Correlates with Quality of Life: the MASK Study
Total Page:16
File Type:pdf, Size:1020Kb
Accepted: 7 September 2017 DOI: 10.1111/all.13307 BRIEF COMMUNICATION The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study J. Bousquet1,2,3 | S. Arnavielhe4 | A. Bedbrook1 | J. Fonseca5,6 | M. Morais Almeida7 | A. Todo Bom8 | I. Annesi-Maesano9 | D. Caimmi10 | P. Demoly10 | P. Devillier11 | V. Siroux12 | E. Menditto13 | G. Passalacqua14 | C. Stellato15 | M. T. Ventura16 | A. A. Cruz17 | F. Sarquis Serpa18 | J. da Silva19 | D. Larenas-Linnemann20 | M. Rodriguez Gonzalez21 | M. T. Burguete Cabanas~ 22 | K. C. Bergmann23,24 | T. Keil25,26 | L. Klimek27 | R. Mosges€ 28 | S. Shamai28 | T. Zuberbier23,24 | M. Bewick29 | D. Price30,31,32 | D. Ryan33 | A. Sheikh34 | J. M. Anto35,36,37 | J. Mullol7 | A. Valero38 | T. Haahtela39 | E. Valovirta38 | W. J. Fokkens40 | P. Kuna41 | B. Samolinski55 | C. Bindslev-Jensen42 | E. Eller42 | S. Bosnic-Anticevich43 | R. E. O’Hehir44,45 | P. V. Tomazic46 | A. Yorgancioglu47,48 | B. Gemicioglu49 | C. Bachert50 | P. W. Hellings51 | I. Kull52 | E. Melen 52 | M. Wickman53 | M. van Eerd54 | G. De Vries54 | the MASK study group 1MACVIA-France, Contre les MAladies Chroniques Pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France 2INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France 3UMR-S 1168, Universite Versailles St-Quentin-en-Yvelines, Montigny le Bretonneux, France 4Kyomed, Montpellier, France 5Faculdade de Medicina, Center for Health Technology and Services Research- CINTESIS, Universidade do Porto, Porto, Portugal 6Allergy Unit, CUF Porto Instituto & Hospital, Porto, Portugal 7Allergy Center, CUF-Descobertas Hospital, Lisboa, Portugal 8Faculty of Medicine, Imunoalergologia, Centro Hospitalar Universitario de Coimbra, University of Coimbra, Coimbra, Portugal 9EPAR U707 INSERM, Paris and EPAR UMR-S UPMC, Paris VI, Paris, France 10UPMC Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, CHRU de Montpellier, Sorbonne Universites, Paris, France 11Laboratoire de Pharmacologie Respiratoire UPRES EA220, Pole^ des Maladies Respiratoires, Hopital^ Foch,Universite Versailles Saint-Quentin, Suresnes, France 12INSERM, IAB, U 1209, Team of Environmental Epidemiology Applied to Reproduction and Respiratory Health, Universite Joseph Fourier, Universite Grenoble Alpes, Grenoble, France 13CIRFF, Center of Pharmacoeconomics, University of Naples Federico II, Naples, Italy 14Personalized Medicine Clinic Asthma & Allergy, Humanitas Research Hospital, Humanitas University, Milan, Italy 15Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Salerno, Italy 16Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy Abbreviations: AHA, Active and Healthy Ageing; AR, allergic rhinitis; ARIA, Allergic Rhinitis and its Impact on Asthma; EIP on AHA, European Innovation Partnership on Active and Healthy Ageing (DG CONNECT, DG Sante); EQ-5D, EuroQuol; ICT, information and communications technology; MACVIA, Contre les MAladies Chroniques pour un VIellissement Actif; MAFEIP, Monitoring and assessment framework for the EIP on AHA; MASK, MACVIA-ARIA Sentinel NetworK; Q9, Question 9 of WPAI-AS; QOL, Quality of life; SF-36, Short Form 36 questions; VAS, visual analogue scale; WPAI-AS, Work Productivity and Activity Impairment in allergy. | Allergy. 2017;1–6. wileyonlinelibrary.com/journal/all © 2017 EAACI and John Wiley and Sons A/S. 1 Published by John Wiley and Sons Ltd. 2 | BOUSQUET ET AL. 17ProAR – Nucleo de Excelencia em Asma, Brasil and GARD Executive Committee, Federal University of Bahia, Salvador, Brazil 18Asthma Reference Center, Escola Superior de Ciencias da Santa Casa de Misericordia de Vitoria, Vitoria, Brazil 19Allergy Service, University Hospital of Federal University of Santa Catarina (HU-UFSC), Florianopolis, Brazil 20Center of Excellence in Asthma and Allergy, Hospital Medica Sur, Mexico, Mexico 21Pediatric Allergy and Clinical Immunology, Hospital Angeles Pedregal, Mexico City, Mexico 22Centro Medico Zambrano Hellion, Monterrey, Mexico 23Comprehensive Allergy-Centre-Charite, Department of Dermatology and Allergy, Charite - Universitatsmedizin€ Berlin, Berlin, Germany 24Global Allergy and Asthma European Network (GA2LEN), Berlin, Germany 25Institute of Social Medicine, Epidemiology and Health Economics, Charite - Universit€atsmedizin Berlin, Berlin, Germany 26Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Wuerzburg, Germany 27Center for Rhinology and Allergology, Wiesbaden, Germany 28Medical Faculty, Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne, Germany 29iQ4U Consultants Ltd, London, UK 30Observational and Pragmatic Research Institute, Singapore, Singapore 31Optimum Patient Care, Cambridge, UK 32Academic Centre of Primary Care, University of Aberdeen, Aberdeen, UK 33Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK 34Asthma UK Centre for Applied Research, Centre of Medical Informatics, Usher Institute of Population Health Sciences and Informatics, The Universityof Edinburgh, Edinburgh, UK 35Centre for Research in Environmental Epidemiology (CREAL), ISGLoBAL, Barcelona, Spain 36IMIM (Hospital del Mar Research Institute), Barcelona, Spain 37CIBER Epidemiologıa y Salud Publica (CIBERESP) & Universitat Pompeu Fabra (UPF), Barcelona, Spain 38Pneumology and Allergy Department Hospital Clınic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain 39Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland 40Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, the Netherlands 41Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland 42Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark 43Woolcock Institute of Medical Research, University of Sydney and Sydney Local Health District, Glebe, NSW, Australia 44Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia 45Department of Immunology, Monash University, Melbourne, VIC, Australia 46Department of ENT, Medical University of Graz, Graz,Austria 47Department of Pulmonology, Celal Bayar University, Manisa, Turkey 48GARD Executive Committee, Manisa, Turkey 49Cerrahpasa Faculty of Medicine, Department of Pulmonary Diseases, Istanbul University, Istanbul, Turkey 50Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium 51Laboratory of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium 52Department of Clinical Science and Education, Sodersjukhuset,€ Karolinska Institutet, Stockholm, Sweden 53Sachs’ Children and Youth Hospital, Sodersjukhuset,€ Stockholm and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden 54Peercode DV, Gerdermalsen, the Netherlands 55Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Poland Correspondence Jean Bousquet, MACVIA-France, Contre les Abstract MAladies Chroniques pour un VIeillissement Mobile technology has been used to appraise allergic rhinitis control, but more data Actif en France European Innovation Partnership on Active and Healthy Ageing are needed. To better assess the importance of mobile technologies in rhinitis control, Reference Site, Montpellier, France. the ARIA (Allergic Rhinitis and its Impact on Asthma) score ranging from 0 to 4 of the Email: [email protected] Allergy Diary was compared with EQ-5D (EuroQuol) and WPAI-AS (Work Productivity Funding information and Activity Impairment in allergy) in 1288 users in 18 countries. This study showed Unrestricted educational grant from Meda, European Union Development and Structural that quality-of-life data (EQ-5D visual analogue scale and WPA-IS Question 9) are funds (Region Languedoc Roussillon), similar in users without rhinitis and in those with mild rhinitis (scores 0-2). Users with MACVIA-LR a score of 3 or 4 had a significant impairment in quality-of-life questionnaires. BOUSQUET ET AL. | 3 Edited by: Thomas Bieber KEYWORDS Allergic Rhinitis and its Impact on Asthma, EuroQuol, MACVIA-ARIA Sentinel NetworK, rhinitis, Work Productivity and Activity Impairment in allergy 1 | INTRODUCTION were asked by their physicians to use the app. However, due to anonymization of data, no specific information was gathered. Measures of allergic rhinitis (AR) control include symptom scores, patients’ self-administered visual analogue scales (VAS), objective 2.3 | Allergy diary measures of nasal obstruction, a recent modification of the ARIA severity classification, or patients’ reported outcomes such as QOL The app collects information on AR symptoms experienced (nasal and 1,2 and scores with several items. Mobile technology has been used ocular), disease type (intermittent/persistent), how symptoms impact 3,4 to appraise AR control. More information is, however, needed to users’ lives, and type(s) of AR treatment used (Table S1). The system fully understand the importance of these novel approaches. has been deployed in 21 countries and in 16 languages